C. David James, PhD

Education

Wright State University, Dayton, Ohio, BS, 1975, Chemistry
Wright State University, Dayton, Ohio, PhD, 1986, Biomedical Science

Professional Experience

• 1986-89
  Post-Doctoral Fellow, Ludwig Institute for Cancer Research, McGill University, Montreal, Quebec Advisor: Webster K. Cavenee, Ph.D., Director- Laboratory of Tumor Biology
• 1989-1991
  Associate then Senior Staff Investigator, Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 1986-89
• 1991-1992
  Assistant then Associate Professor, Dept. of Neurosurgery and Dept. of Pediatrics, Emory University School of Medicine Atlanta, GA
• 1996-2006
  Associate Professor then Professor, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
• 2006-
  Berthold and Belle Guggenhime Professor of Neurological Surgery, Department of Neurological Surgery, University of California San Francisco

Honors & Awards

• 1996-present
  Editorial Board, Journal of Neuropathology and Experimental Neurology
• 1997-present
  Scientific Advisory Committee, Pediatric Brain Tumor Foundation of the United States
• 1998-present
  Editorial Board, Neuro-Oncology
• 2000-present
  Editorial Board, Clinical Cancer Research
• 2000-2005
  Member, Clinical Neuroimmunology and Brain Tumors (CNBT) Study Section, NINDS
• 2005-present
  Member, Parent Committee, Specialized Projects of Research Excellence (SPORE), NCI

Selected Publications

1. Wade A, Robinson AE, Engler JR, Petritsch C, James CD, Phillips JJ. Proteoglycans and their roles in brain cancer. FEBS J. 2013 May; 280(10):2399-417.
   View on PubMed
2. Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013 Feb; 15(2):189-97.
   View on PubMed
3. Silber J, Hashizume R, Felix T, Hariono S, Yu M, Berger MS, Huse JT, Vandenberg SR, James CD, Hodgson JG, Gupta N. Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol. 2013 Jan; 15(1):83-90.
   View on PubMed
4. Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, Mueller S, James CD, Gupta N. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neurooncol. 2012 Dec; 110(3):305-13.
   View on PubMed
5. Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One. 2012; 7(8):e43339.
   View on PubMed
6. Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 Tesla. Neuro Oncol. 2012 Aug; 14(8):1050-61.
   View on PubMed
7. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012 May 29; 109(22):8710-5.
   View on PubMed
8. Serwer LP, James CD. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev. 2012 May 15; 64(7):590-7.
   View on PubMed
9. Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados M, James CD, Gupta N. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J Neurooncol. 2012 May; 108(1):29-35.
   View on PubMed
10. Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, Perry A, Phillips JJ. Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. J Neuropathol Exp Neurol. 2012 Jan; 71(1):83-9.
    View on PubMed
11. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):315-25.
    View on PubMed
12. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res. 2011 Dec 15; 17(24):7595-604.
    View on PubMed
13. Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011 Dec; 13(12):1288-95.
    View on PubMed
14. Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen SM. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage. 2012 Jan 2; 59(1):193-201.
    View on PubMed
15. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging. 2011 Jun; 33(6):1284-90.
    View on PubMed
16. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011 Apr; 13(4):384-92.
    View on PubMed
17. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal. 2010; 3(147):ra81.
    View on PubMed
18. Serwer L, Hashizume R, Ozawa T, James CD. Systemic and local drug delivery for treating diseases of the central nervous system in rodent models. J Vis Exp. 2010; (42).
    View on PubMed
19. Ozawa T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp. 2010; (41).
    View on PubMed
20. Zhu X, Bidlingmaier S, Hashizume R, James CD, Berger MS, Liu B. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther. 2010 Jul; 9(7):2131-41.
    View on PubMed

View on UCSF Profiles